A polished capabilities deck is not a manufacturing plan. When evaluating cell and gene therapy CDMOs, start with the work your program needs, the evidence behind each capability, and the people who will own delivery.
Build a shortlist around those requirements before comparing proposals. This guide gives business leaders a way to structure the decision alongside their scientific, quality, regulatory, and legal teams—not a substitute for those teams' assessments.
What do cell and gene therapy CDMOs do?
Cell and gene therapy CDMOs are contract development and manufacturing organizations that support development and manufacturing for cell and gene therapy programs. Evaluate them against your product, stage, required services, quality expectations, transfer plan, and delivery needs. Ask for project-relevant evidence and a written scope before choosing a partner.
Why start with your program instead of a vendor list?
Use the selection process to test whether a partner’s proposed work matches your next program milestone. Do not make a broad service menu your buying specification. Write down what you need delivered, what your team will provide, and what evidence you expect before approving the work.
The supplied service descriptions illustrate different scopes: Charles River describes a combined CDMO and CRO offering, while Patheon’s advanced therapies description lists viral vectors, plasmid DNA, cell therapies, and mRNA. Use those categories to frame questions, not to infer that either provider fits your program.
If your leadership team needs the broader outsourcing vocabulary first, use CDMO explained. For this decision, treat CDMO and CMO labels as starting points. Ask each bidder which development and manufacturing tasks its proposal actually includes.
Before approaching cell and gene therapy CDMOs, prepare a short program brief. Specify the product type, development stage, intended manufacturing site or region, target milestone, expected demand, and existing process information. Separate firm requirements from preferences so bidders can explain genuine tradeoffs.
What evidence should you request from each partner?
Compare cell and gene therapy CDMOs against the same evidence requests. Ask for material tied to the proposed team, site, and service—not just the company as a whole. Where confidentiality limits disclosure, discuss a controlled review rather than accepting a marketing statement as a substitute.
| Decision area | Question to ask | Material to request |
|---|---|---|
| Product and process fit | Which parts of our program match your relevant experience? | A project-specific explanation, with supporting records available for appropriate review. |
| Development scope | What work must be completed before manufacturing can begin? | A development plan with assumptions, deliverables, and decision points. |
| Analytical work | Who will develop, transfer, perform, and review the agreed tests? | A responsibility map and a plan for resolving method gaps. |
| Manufacturing site | Where will each task happen, and what is available there? | A site-specific scope, named contacts, and a proposed diligence process. |
| Capacity and timing | What must happen before our proposed start date becomes a commitment? | A schedule showing dependencies and reservation terms. |
| Delivery ownership | Who is accountable when a milestone is at risk? | A governance plan with escalation contacts and response expectations. |
Keep critical requirements separate from weighted preferences. Do not let a strong commercial presentation offset an unresolved requirement that your technical or quality team considers essential.
How should the work move from selection to manufacturing?
Ask cell and gene therapy CDMOs to walk through your proposed project in sequence. Request the inputs, outputs, owner, and acceptance criteria for each step. The goal is a shared delivery plan, not a generic diagram showing every service the provider sells.
First, close the information gaps
Have your CMC lead assemble the available process description, analytical information, material requirements, and development history. Ask the receiving team to identify missing inputs. Put those gaps into the proposal so both sides can distinguish planned work from unresolved assumptions.
Next, agree on the transfer package
Define what the partner needs to receive, who prepares it, and how the receiving team will assess it. Request a document list, method-transfer plan, training needs, and a route for answering technical questions. Name the person who can accept each transfer deliverable.
Then, define the path to the next milestone
Ask for a work plan that links development tasks, manufacturing activities, testing, document review, and delivery. If fill-finish, storage, or shipping is part of the project, identify its owner and any external handoff. Do not assume that an end-to-end proposal keeps every task at one site.
Require proposed cell and gene therapy CDMOs to explain what changes if a dependency slips. Agree on when your team will receive notice, what alternatives will be assessed, and who can approve a revised plan. Leave room for technical judgment without leaving accountability undefined.
Who owns quality, documentation, and changes?
Bring your quality and regulatory teams into the evaluation before commercial terms are settled. Ask them to define the project-specific review, documentation, and oversight expectations that belong in the proposed arrangement.
For cell and gene therapy CDMOs, make responsibility questions explicit: who reviews records, investigates deviations, assesses proposed changes, communicates with your team, and maintains the agreed documentation? Have qualified teams assess the answers against your product, stage, and intended markets.
Request a practical example of the proposed escalation process. Use a hypothetical missed milestone or requested process change and ask who would notify whom, what information would be shared, and who would make the decision. Treat the exercise as a discussion tool, not proof of past performance.
Keep scientific and quality decisions with the people qualified to make them. Business leaders should make sure those decisions have clear owners, sufficient review time, and a visible place in the project schedule.
How should you compare costs and contract terms?
Compare proposals from cell and gene therapy CDMOs on a shared scope before comparing their totals. Ask each bidder to separate included work, optional work, pass-through expenses, assumptions, and exclusions. Build your commercial comparison from that breakdown.
Request line items for the activities your program needs: development, transfer, analytical work, manufacturing, documentation, and any fill-finish or logistics responsibilities. Ask what would trigger additional work and how a change would be priced and authorized.
Review capacity reservation, cancellation, rescheduling, payment milestones, and termination terms with your legal and procurement teams. Ask how the agreement handles a delayed input from your side as well as a delayed deliverable from the partner.
Include an exit discussion. Specify access to project records, ownership and permitted use of process information, transfer assistance, and the treatment of materials if the relationship ends. Request those terms before signing rather than leaving them for a later negotiation.
For a leadership review, present the proposed fee alongside open assumptions and unpriced work. Label the comparison as a planning estimate until the scope and relevant terms are agreed; do not present a headline quote as a complete program budget.
What mistakes should the selection team avoid?
Do not rank cell and gene therapy CDMOs by breadth of services alone. Test whether the proposed work, people, and site fit your program. Keep your shortlist tied to that assessment as proposals change.
- Accepting company-wide evidence for a site-specific decision. Ask which location and team the supporting material concerns.
- Comparing unequal scopes. Reconcile exclusions and sponsor responsibilities before debating price.
- Treating an indicative date as a reserved slot. Ask what commitment the schedule represents and what conditions apply.
- Leaving analytical work until later. Have your scientific team assess the proposed testing responsibilities during diligence.
- Ignoring handoffs. Name the owner of each task performed by another site or subcontractor.
- Ending diligence at contract signature. Carry open questions into an owned action log with due dates.
How should you measure whether the partnership is working?
Agree on measures with cell and gene therapy CDMOs before work begins. Tie them to your approved project plan, and define how each measure will be calculated. Use the dashboard to support decisions, not to substitute for technical review.
| Measure | Definition to agree | Review question |
|---|---|---|
| Milestone delivery | Accepted deliverables completed against the agreed baseline. | Which dependency explains any variance? |
| Transfer readiness | Required transfer items accepted, with remaining gaps assigned. | What still prevents the next activity from starting? |
| Issue management | Open issues by owner, age, agreed priority, and due date. | Which issue requires a leadership decision? |
| Scope and budget | Approved changes and current forecast against the agreed scope. | What new work has been authorized, and why? |
| Document delivery | Agreed records delivered and accepted for their intended use. | Which outstanding document affects the next milestone? |
Have your technical and quality teams select any additional process or batch measures. Do not import a generic success-rate target from another program. Record the baseline, reporting period, data source, and decision owner for every measure you retain.
What should leadership see before choosing a partner?
End the evaluation of cell and gene therapy CDMOs with a short decision memo. Show the proposed partner, scope, supporting evidence, unresolved questions, commercial assumptions, and reasons for rejecting the alternatives. Assign an owner and next step to every remaining issue.
Ask the decision team to distinguish accepted tradeoffs from unanswered questions. If a critical requirement remains unresolved, request the missing evidence or revise the scope before advancing. Do not hide the gap inside an average score.
For manufacturers presenting their own capabilities, apply the same discipline to buyer-facing communication: make scope, site, evidence, and next steps easy to find. That is a useful starting point for life sciences marketing, but a clear website is not a substitute for technical diligence.
Choose the partner against the work you have defined. Carry the agreed responsibilities and acceptance criteria into project governance so the selection decision and delivery plan stay connected.
About Bob Generale
Bob Generale is President of Percepture.
